Posts by tag
personalised medicine
Nanotechnology is steadily expanding its many roles in tackling cancer
A nanomedicine, as defined by the US National Institutes of Health, is a “highly specific medical intervention at the molecular scale for curing disease or repairing damaged tissues… ” For…
How organoids could help match treatments to tumours
When diagnosed with cancer, few things are more important than having confidence that the treatment you are prescribed is the best possible option for you. For many cancers, particularly the…
UK consensus group calls for biomarker testing at point of diagnosis
All cancer patients should be offered genomic profiling of their tumours at the point of diagnosis and during treatment to shape care and track how their disease evolves and responds…
Precision care: supporting our patients starts with asking them what they want and need
Two weeks after receiving a brain tumour diagnosis, Martin was copied into an email from one of his healthcare team telling his GP that Martin was “understandably devastated by his…
Evolution of the doctor-patient relationship: from ancient times to the personalised medicine era
The nature of the doctor–patient relationship has gone through various phases in history, based on the changing role of the physician in the community, as well as progress in medicine…
Woman or man? Is precision medicine overlooking key biological differences?
“Something that hit me pretty early during my residency as an oncologist was that sex in most cases is a clear-cut binary, pretty obvious biological variable affecting attitudes as well…
Machine learning holds key to personalised cancer drugs
Researchers have developed a machine learning (ML) algorithm that can be used to rank the effectiveness of different drugs in reducing cancer cell growth for individual patients. In Nature Communications…
Updated MINDACT results reveal chemotherapy benefit in some breast cancers varies by age
Updated results of the MINDACT trial confirm that women with early-stage breast cancer, who were assessed to be at high clinical but low genomic risk for recurrence, and did not…
Raed Al Dieri: Taking pathology from bit part to key player on the European oncology scene
The man steering the organisation dubbed “the leading force in European pathology” is not one to dwell on the negative. Raed Al Dieri, Director General of the European Society of…
Delivering the best cancer care during the pandemic
Key messages from the e-ESO faculty On March 18, the European School of Oncology presented an interactive webinar on how to do this, drawing on the limited data available, the…